Infectech (Sharon, Pennsylvania) – a nano-biotechnology company engaged in the research and development of technologies for the production of bacteria – and disease-testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials – reported that it has changed its name to NanoLogix.

The name change was approved at a March 30 special meeting, during which a proposal to reverse split the company's common stock was turned down, Infectech said, "due to resistance from minority shareholders."

NanoLogix's patents have nanotechnology applications in hydrogen gas production, medical drugs/devices, bio-defense sensors and bioremediation.